Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-027820
Filing Date
2023-08-07
Accepted
2023-08-07 16:55:43
Documents
70
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q bcrx-20230630.htm   iXBRL 10-Q 1276640
2 EX-10.1 exhibit101-pharmakonloanag.htm EX-10.1 1404090
3 EX-10.3 exhibit103-esppar20230707.htm EX-10.3 73465
4 EX-31.1 bcrx-20230630xexx311.htm EX-31.1 9585
5 EX-31.2 bcrx-20230630xexx312.htm EX-31.2 9559
6 EX-32.1 bcrx-20230630xexx321.htm EX-32.1 4626
7 EX-32.2 bcrx-20230630xexx322.htm EX-32.2 4600
  Complete submission text file 0001628280-23-027820.txt   8618316

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcrx-20230630.xsd EX-101.SCH 58979
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcrx-20230630_cal.xml EX-101.CAL 52822
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcrx-20230630_def.xml EX-101.DEF 232750
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcrx-20230630_lab.xml EX-101.LAB 711707
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcrx-20230630_pre.xml EX-101.PRE 422718
64 EXTRACTED XBRL INSTANCE DOCUMENT bcrx-20230630_htm.xml XML 896721
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23186 | Film No.: 231148274
SIC: 2836 Biological Products, (No Diagnostic Substances)